Fed Circuit affirms generic maker’s win over Eagle
11-05-2020
Teva and Mylan implore Fed Circuit not to stay immunity ruling
07-11-2018
Bill Perry / Shutterstock.com
The US Court of Appeals for the Federal Circuit has narrowed the landscape in which patent infringement suits over generic drugs suits can be filed, in a ruling handed down yesterday, November 5.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Federal Circuit, patents, generic, venue, Mylan, MPI, Valeant, Dow, Kaken, Hatch-Waxman Act
